LifeVantage Co. (NASDAQ:LFVN) Stock Holdings Increased by Barclays PLC

Barclays PLC boosted its position in shares of LifeVantage Co. (NASDAQ:LFVN) by 38.2% during the 3rd quarter, HoldingsChannel reports. The firm owned 41,966 shares of the company’s stock after buying an additional 11,608 shares during the quarter. Barclays PLC’s holdings in LifeVantage were worth $507,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of LFVN. Ritholtz Wealth Management increased its position in LifeVantage by 62.0% during the third quarter. Ritholtz Wealth Management now owns 28,666 shares of the company’s stock worth $346,000 after buying an additional 10,974 shares during the last quarter. HighTower Advisors LLC acquired a new position in shares of LifeVantage in the 3rd quarter valued at $638,000. Capital Management Corp VA acquired a new stake in LifeVantage in the 3rd quarter valued at $5,073,000. Finally, Renaissance Technologies LLC lifted its holdings in LifeVantage by 2.1% during the 2nd quarter. Renaissance Technologies LLC now owns 855,118 shares of the company’s stock valued at $5,490,000 after purchasing an additional 17,300 shares during the last quarter. Hedge funds and other institutional investors own 35.32% of the company’s stock.

LifeVantage Price Performance

Shares of LFVN stock opened at $17.66 on Friday. The company has a fifty day moving average price of $14.96 and a two-hundred day moving average price of $10.94. The stock has a market cap of $221.19 million, a P/E ratio of 55.19 and a beta of 0.87. LifeVantage Co. has a one year low of $5.22 and a one year high of $19.06.

LifeVantage (NASDAQ:LFVN) last released its quarterly earnings results on Tuesday, October 29th. The company reported $0.15 EPS for the quarter, meeting the consensus estimate of $0.15. LifeVantage had a net margin of 2.11% and a return on equity of 29.24%. The business had revenue of $47.21 million for the quarter.

LifeVantage Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, December 16th. Stockholders of record on Monday, December 2nd were paid a dividend of $0.04 per share. This represents a $0.16 annualized dividend and a dividend yield of 0.91%. The ex-dividend date was Monday, December 2nd. LifeVantage’s payout ratio is currently 50.00%.

Analyst Upgrades and Downgrades

Separately, Lake Street Capital initiated coverage on shares of LifeVantage in a research note on Thursday, December 19th. They issued a “buy” rating and a $26.00 target price on the stock.

LifeVantage Profile

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.